Literature DB >> 19434609

Redirecting lentiviral vectors by insertion of integrin-tageting peptides into envelope proteins.

Kouki Morizono1, Nonia Pariente, Yiming Xie, Irvin S Y Chen.   

Abstract

BACKGROUND: Targeting gene therapy vectors that can home in on desired cell and tissue types in vivo comprise the ultimate gene delivery system. We have previously developed targeting lentiviral vectors by pseudotyping vectors with modified Sindbis virus envelope proteins. The envelope protein contains the Fc-binding region of protein A (ZZ domain), so the virus can be conjugated with antibodies. The conjugated antibody mediates specific transduction of the cells and tissues expressing the target antigens, both in vitro and in vivo. However, more stable conjugation of targeting molecules would be optimal for use in immunocompetent animals, as well as in humans.
METHODS: We inserted integrin-targeting peptides into two sites of the targeting envelope proteins and determined whether the peptides serve as receptor-binding regions of the envelope proteins and redirect the pseudotyped viruses.
RESULTS: The integrin-targeting peptides can mediate binding to cells via the interaction with integrins on target cells and transduction. Peptides with a higher binding affinity increase titers of pseudotyped virus. We found two regions on the envelope protein that can accommodate insertion and serve as receptor-binding regions. Combining the peptides in two distinct regions increased the titers of the virus.
CONCLUSIONS: Successful incorporation of targeting molecules into the envelope protein will broaden the application of targeting vectors for a wide variety of experimental and clinical settings. 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19434609      PMCID: PMC2834586          DOI: 10.1002/jgm.1339

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  42 in total

1.  A versatile and potentially general approach to the targeting of specific cell types by retroviruses: application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses.

Authors:  P Roux; P Jeanteur; M Piechaczyk
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

2.  Targeting a retroviral vector in the absence of a known cell-targeting ligand.

Authors:  Keith Bupp; Monica J Roth
Journal:  Hum Gene Ther       Date:  2003-11-01       Impact factor: 5.695

3.  Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation.

Authors:  Georgette Thumshirn; Ulrich Hersel; Simon L Goodman; Horst Kessler
Journal:  Chemistry       Date:  2003-06-16       Impact factor: 5.236

Review 4.  New perspectives in cell adhesion: RGD and integrins.

Authors:  E Ruoslahti; M D Pierschbacher
Journal:  Science       Date:  1987-10-23       Impact factor: 47.728

5.  Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins.

Authors:  M Marin; D Noël; S Valsesia-Wittman; F Brockly; M Etienne-Julan; S Russell; F L Cosset; M Piechaczyk
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

6.  Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery.

Authors:  N V Somia; M Zoppé; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

7.  Tissue-specific targeting of retroviral vectors through ligand-receptor interactions.

Authors:  N Kasahara; A M Dozy; Y W Kan
Journal:  Science       Date:  1994-11-25       Impact factor: 47.728

8.  Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors.

Authors:  S Valsesia-Wittmann; A Drynda; G Deléage; M Aumailley; J M Heard; O Danos; G Verdier; F L Cosset
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

9.  Targeting of retroviral vectors through protease-substrate interactions.

Authors:  B H Nilson; F J Morling; F L Cosset; S J Russell
Journal:  Gene Ther       Date:  1996-04       Impact factor: 5.250

10.  Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice.

Authors:  Antonia Follenzi; Manuela Battaglia; Angelo Lombardo; Andrea Annoni; Maria Grazia Roncarolo; Luigi Naldini
Journal:  Blood       Date:  2003-12-30       Impact factor: 22.113

View more
  16 in total

1.  DARPins: an efficient targeting domain for lentiviral vectors.

Authors:  Robert C Münch; Michael D Mühlebach; Thomas Schaser; Sabrina Kneissl; Christian Jost; Andreas Plückthun; Klaus Cichutek; Christian J Buchholz
Journal:  Mol Ther       Date:  2011-01-11       Impact factor: 11.454

2.  Redirecting lentiviral vectors pseudotyped with Sindbis virus-derived envelope proteins to DC-SIGN by modification of N-linked glycans of envelope proteins.

Authors:  Kouki Morizono; Amy Ku; Yiming Xie; Airi Harui; Sam K P Kung; Michael D Roth; Benhur Lee; Irvin S Y Chen
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

3.  Role of phosphatidylserine receptors in enveloped virus infection.

Authors:  Kouki Morizono; Irvin S Y Chen
Journal:  J Virol       Date:  2014-01-29       Impact factor: 5.103

4.  Sindbis Virus-Pseudotyped Lentiviral Vectors Carrying VEGFR2-Specific Nanobody for Potential Transductional Targeting of Tumor Vasculature.

Authors:  Roshank Ahani; Farzin Roohvand; Reza Ahangari Cohan; Mohammad Hossein Etemadzadeh; Nasir Mohajel; Mahdi Behdani; Zahra Shahosseini; Navid Madani; Kayhan Azadmanesh
Journal:  Mol Biotechnol       Date:  2016-11       Impact factor: 2.695

Review 5.  Receptors and tropisms of envelope viruses.

Authors:  Kouki Morizono; Irvin S Y Chen
Journal:  Curr Opin Virol       Date:  2011-07       Impact factor: 7.090

6.  Retargeting vesicular stomatitis virus glycoprotein pseudotyped lentiviral vectors with enhanced stability by in situ synthesized polymer shell.

Authors:  Min Liang; Ming Yan; Yunfeng Lu; Irvin S Y Chen
Journal:  Hum Gene Ther Methods       Date:  2013-02       Impact factor: 2.396

7.  Role of the phosphatidylserine receptor TIM-1 in enveloped-virus entry.

Authors:  Sven Moller-Tank; Andrew S Kondratowicz; Robert A Davey; Paul D Rennert; Wendy Maury
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

8.  Versatile targeting system for lentiviral vectors involving biotinylated targeting molecules.

Authors:  Kathy Situ; Bernadette Anne Chua; Song Yi Bae; Aaron Samuel Meyer; Kouki Morizono
Journal:  Virology       Date:  2018-10-02       Impact factor: 3.616

9.  Characterizing functional domains for TIM-mediated enveloped virus entry.

Authors:  Sven Moller-Tank; Lorraine M Albritton; Paul D Rennert; Wendy Maury
Journal:  J Virol       Date:  2014-04-02       Impact factor: 5.103

10.  Cell-specific targeting of lentiviral vectors mediated by fusion proteins derived from Sindbis virus, vesicular stomatitis virus, or avian sarcoma/leukosis virus.

Authors:  Xian-Yang Zhang; Robert H Kutner; Agnieszka Bialkowska; Michael P Marino; William B Klimstra; Jakob Reiser
Journal:  Retrovirology       Date:  2010-01-25       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.